Company intelligence / Profile preview

TCG Labs-Soleil

South San Francisco, California, United Statestcglsoleil.com ↗

Ownership: Private
Employees: ~20
Development stage: Preclinical

Overview

TCG Labs-Soleil has established a $400M+ fund to create and advance single biologic asset companies from ideation through clinical proof of concept. The model integrates an evergreen R&D hub with a dedicated venture fund. Programs are advanced until they reach human proof of concept before being positioned for strategic partnerships or acquisition by pharma/biotech partners. No specific clinical results disclosed yet as the initiative launched in 2024.

Therapeutic areas: Other
Modalities: Biologics (including antibodies and protein therapeutics)
Industry: Investors

Partnerships

The Column Group

Beyond the preview

Go deeper on TCG Labs-Soleil.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TCG Labs-Soleil.

Explore the full profile